Yonsei Med J.  2012 Mar;53(2):439-441. 10.3349/ymj.2012.53.2.439.

Antimicrobial Susceptibility of Stenotrophomonas maltophilia Isolates from a Korean Tertiary Care Hospital

• Chung HS
• Hong SG
• Lee Y
• Kim M
• Yong D
• Jeong SH
• Lee K
• Chong Y

• KMID: 1120215
• DOI: http://doi.org/10.3349/ymj.2012.53.2.439

Abstract

We determined the antimicrobial susceptibility of 90 clinical isolates of Stenotrophomonas maltophilia collected in 2009 at a tertiary care hospital in Korea. Trimethoprim-sulfamethoxazole, minocycline, and levofloxacin were active against most of the isolates tested. Moxifloxacin and tigecycline were also active and hold promise as therapeutic options for S. maltophilia infections.

Keyword

Stenotrophomonas maltophilia; antimicrobial susceptibility; trimethoprim-sulfamethoxazole; levofloxacin; minocycline

MeSH Terms

Anti-Infective Agents/*pharmacology
Hospitals
Korea
Microbial Sensitivity Tests
Minocycline/pharmacology
Ofloxacin/pharmacology
Stenotrophomonas maltophilia/*drug effects
Trimethoprim-Sulfamethoxazole Combination/pharmacology

Reference

1. Looney WJ, Narita M, Mühlemann K. Stenotrophomonas maltophilia: an emerging opportunist human pathogen. Lancet Infect Dis. 2009. 9:312–323.

2. Sader HS, Jones RN. Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli. Int J Antimicrob Agents. 2005. 25:95–109.

3. Jones RN, Sader HS, Beach ML. Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18569 strains non-fermentative Gram-negative bacilli isolated in the SENTRY Antimicrobial Surveillance Program (1997-2001). Int J Antimicrob Agents. 2003. 22:551–556.

4. Nicodemo AC, Paez JI. Antimicrobial therapy for Stenotrophomonas maltophilia infections. Eur J Clin Microbiol Infect Dis. 2007. 26:229–237.

5. Wang WS, Liu CP, Lee CM, Huang FY. Stenotrophomonas maltophilia bacteremia in adults: four years' experience in a medical center in northern Taiwan. J Microbiol Immunol Infect. 2004. 37:359–365.

6. BSAC Methods for antimicrobial susceptibility testing. access on June 2011. Available at http://www.bsac.org.uk/Susceptibility+Testing/GUIDELINES+Standardized+Disc+Susceptibility+Testing+Method.

7. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-first informational supplement, M100-S21. 2011. Wanye, PA: Clinical and Laboratory Standards Institute.

8. Song JH, Sung JY, Kwon KC, Park JW, Cho HH, Shin SY, et al. Analysis of acquired resistance genes in Stenotrophomonas maltophilia. Korean J Lab Med. 2010. 30:295–300.

9. Seol SY, Jang KS, Jeong OG, Cho ER, Kim NH, Yu HS, et al. Antimicrobial resistance and molecular epidemiologic characteristics of Stenotrophomonas maltophilia isolated from clinical specimens. J Korean Soc Microbiol. 2000. 35:239–250.

10. Livermore DM, Hope R, Brick G, Lillie M, Reynolds R. BSAC Working Parties on Resistance Surveillance. Non-susceptibility trends among Pseudomonas aeruginosa and other non-fermentative Gram-negative bacteria from bacteraemias in the UK and Ireland, 2001-06. J Antimicrob Chemother. 2008. 62:Suppl 2. ii55–ii63.

11. Farrell DJ, Sader HS, Jones RN. Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections. Antimicrob Agents Chemother. 2010. 54:2735–2737.

12. Cantón R, Valdezate S, Vindel A, Sánchez Del Saz B, Maíz L, Baquero F. Antimicrobial susceptibility profile of molecular typed cystic fibrosis Stenotrophomonas maltophilia isolates and differences with noncystic fibrosis isolates. Pediatr Pulmonol. 2003. 35:99–107.

13. Gülmez D, Hascelik G. Stenotrophomonas maltophilia: antimicrobial resistance and molecular typing of an emerging pathogen in a Turkish university hospital. Clin Microbiol Infect. 2005. 11:880–886.

14. Valenza G, Tappe D, Turnwald D, Frosch M, König C, Hebestreit H, et al. Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis. J Cyst Fibros. 2008. 7:123–127.

15. Galles AC, Jones RN, Sader HS. Antimicrobial susceptibility profile of contemporary clinical strains of Stenotrophomonas maltophilia isolates: can moxifloxacin activity be predicted by levofloxacin MIC results? J Chemother. 2008. 20:38–42.

16. Valdezate S, Vindel A, Loza E, Baquero F, Cantón R. Antimicrobial susceptibilities of unique Stenotrophomonas maltophilia clinical strains. Antimicrob Agents Chemother. 2001. 45:1581–1584.

17. Vartivarian S, Anaissie E, Bodey G, Sprigg H, Rolston K. A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapy. Antimicrob Agents Chemother. 1994. 38:624–627.